Analysts Set Illumina, Inc. (NASDAQ:ILMN) Price Target at $165.95

Shares of Illumina, Inc. (NASDAQ:ILMN) have received an average recommendation of “Moderate Buy” from the twenty ratings firms that are presently covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $165.95.

ILMN has been the subject of a number of recent research reports. Stephens raised their price objective on shares of Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. Hsbc Global Res raised Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price target for the company in a research report on Thursday, October 17th. TD Cowen increased their price objective on Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Citigroup cut Illumina from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $190.00 to $165.00 in a research report on Wednesday, December 11th. Finally, Morgan Stanley restated an “equal weight” rating and issued a $156.00 target price on shares of Illumina in a report on Tuesday, November 12th.

Hedge Funds Weigh In On Illumina

Several hedge funds and other institutional investors have recently modified their holdings of ILMN. B. Riley Wealth Advisors Inc. raised its holdings in Illumina by 66.8% in the third quarter. B. Riley Wealth Advisors Inc. now owns 11,973 shares of the life sciences company’s stock valued at $1,582,000 after buying an additional 4,797 shares during the period. Tidal Investments LLC raised its stake in shares of Illumina by 38.0% in the 3rd quarter. Tidal Investments LLC now owns 4,449 shares of the life sciences company’s stock valued at $580,000 after acquiring an additional 1,226 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in shares of Illumina during the 3rd quarter valued at $772,000. Sanctuary Advisors LLC boosted its position in Illumina by 2.0% during the 3rd quarter. Sanctuary Advisors LLC now owns 22,778 shares of the life sciences company’s stock worth $3,192,000 after purchasing an additional 450 shares during the period. Finally, M&T Bank Corp increased its holdings in Illumina by 3.4% in the 3rd quarter. M&T Bank Corp now owns 54,378 shares of the life sciences company’s stock valued at $7,091,000 after purchasing an additional 1,769 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Stock Up 0.2 %

ILMN opened at $135.27 on Thursday. Illumina has a one year low of $100.08 and a one year high of $156.66. The company has a market cap of $21.45 billion, a price-to-earnings ratio of -13.58 and a beta of 1.11. The business’s fifty day moving average is $142.82 and its two-hundred day moving average is $130.52. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same period in the previous year, the firm earned $0.33 EPS. The business’s revenue for the quarter was down 3.5% compared to the same quarter last year. Analysts anticipate that Illumina will post 4.11 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.